Antiangiogenic Effects of Axitinib, an Inhibitor of Vascular Endothelial Growth Factor Receptor Tyrosine Kinase, on Laser-Induced Choroidal Neovascularization in Mice

Current Eye Research

Volumn 38, Issue 1, 2013, Pages 119-127

  Kang, Seungbum ^a,b   Roh, Chang Rae ^a,b   Cho, Won Kyung ^a,b   Park, Ki Cheol ^b   Yang, Keum Jin ^b   Choi, Hyun Su ^b   Kim, So Hee ^b   Roh, Young Jung ^a,c  

^a Department of Ophthalmology and Visual Science ^*  (South Korea)

^b Daejeon St Mary's Hospital   (South Korea)

^c The Catholic University of Korea   (South Korea)

Author keywords

Angiogenesis; Axitinib; Receptor tyrosine kinase; Vascular endothelial growth factor

Indexed keywords

AXITINIB; FLUORESCEIN ISOTHIOCYANATE DEXTRAN; ISOLECTIN B4;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIANGIOGENIC ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; IMMUNOFLUORESCENCE; LASER COAGULATION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; REMISSION; RETINA MACULA AGE RELATED DEGENERATION; SUBRETINAL NEOVASCULARIZATION;

ANIMALS; CHOROID; CHOROIDAL NEOVASCULARIZATION; DISEASE MODELS, ANIMAL; IMIDAZOLES; INDAZOLES; LASER COAGULATION; MALE; MICE; MICE, INBRED C57BL; MICROSCOPY, CONFOCAL; PROTEIN KINASE INHIBITORS; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1;

EID: 84872041595     PISSN: 02713683     EISSN: 14602202     Source Type: Journal    
DOI: 10.3109/02713683.2012.727520     Document Type: Article

References (31)

1. Amin R, Puklin JE, Frank RN. Growth factor localization in choroidal neovascular membranes of age-related macular degeneration. Invest Ophthalmol Vis Sci 1994;35:3178-3188
2. Funk M, Karl D, Georgopoulos M, Benesch T, Sacu S, Polak K et al. Neovascular age-related macular degeneration: Intraocular cytokines and growth factors and the influence of therapy with ranibizumab. Ophthalmology 2009;116:2393-2399
3. Lambooij AC, van Wely KH, Lindenbergh-Kortleve DJ, Kuijpers RW, Kliffen M, Mooy CM. Insulin-like growth factor-I and its receptor in neovascular age-related macular degeneration. Invest Ophthalmol Vis Sci 2003;44:2192-2198
4. Ishibashi T, Hata Y, Yoshikawa H et al. Expression of vascular endothelial growth factor in experimental choroidal neovascularization. Graefes Arch Clin Exp Ophthalmol 1997;235:159-167
5. Achen MG, Jeltsch M, Kukk E, Nakagawa K, Sueishi K, Inomata H. Vascular endothelial growth factor D (VEGF-D) is a ligand for the tyrosine kinases VEGF receptor 2 (Flk1) and VEGF receptor 3 (Flt4). Proc Natl Acad Sci USA 1998;95:548-553
6. Waltenberger J, Claesson-Welsh L, Siegbahn A, Shibuya M, Heldin CH. Different signal transduction properties of KDR and Flt1, two receptors for vascular endothelial growth factor. J Biol Chem 1994;269:26988-26995
7. Takahashi T, Ueno H, Shibuya M. VEGF activates protein kinase C-dependent, but Ras-independent Raf-MEK-MAP kinase pathway for DNA synthesis in primary endothelial cells. Oncogene 1999;18:2221-2230
8. Takahashi T, Yamaguchi S, Chida K, Shibuya M. A single autophosphorylation site on KDR/Flk-1 is essential for VEGF-Adependent activation of PLC-gamma and DNA synthesis in vascular endothelial cells. EMBO J 2001;20:2768-2778
9. Gerber HP, McMurtrey A, Kowalski J, Yan M, Keyt BA, Dixit V et al. Vascular endothelial growth factor regulates endothelial cell survival through the phosphatidylinositol 3'-kinase/ Akt signal transduction pathway. Requirement for Flk-1/ KDR activation. J Biol Chem 1998;273:30336-30343
10. Fulton D, Gratton JP, McCabe TJ, Fontana J, Fujio Y, Walsh K et al. Regulation of endothelium-derived nitric oxide production by the protein kinase Akt. Nature 1999;399:597-601
11. Rousseau S, Houle F, Landry J, Huot J. p38 MAP kinase activation by vascular endothelial growth factor mediates actin reorganization and cell migration in human endothelial cells. Oncogene 1997;15:2169-2177
12. Hu-Lowe DD, Zou HY, Grazzini ML, Hallin ME, Wickman GR, Amundson K et al. Nonclinical antiangiogenesis and antitumor activities of axitinib (AG-013736), an oral, potent, and selective inhibitor of vascular endothelial growth factor receptor tyrosine kinases 1, 2, 3. Clin Cancer Res 2008;14:7272-7283
13. Liu G, Rugo HS, Wilding G, Evelhoch JL, Ng C, Jackson E, Kelcz F et al. Dynamic contrast-enhanced magnetic resonance imaging as a pharmacodynamic measure of response after acute dosing of AG-013736, an oral angiogenesis inhibitor, in patients with advanced solid tumors: Results from a phase I study. J Clin Oncol 2005;23:5464-5473
14. Wilmes LJ, Pallavicini MG, Fleming LM, Gibbs J, Wang D, Li KL et al. AG-013736, a novel inhibitor of VEGF receptor tyrosine kinases, inhibits breast cancer growth and decreases vascular permeability as detected by dynamic contrastenhanced magnetic resonance imaging. Magn Reson Imaging 2007;25:319-327
15. Nakahara T, Norberg SM, Shalinsky DR, Hu-Lowe DD, McDonald DM. Effect of inhibition of vascular endothelial growth factor signaling on distribution of extravasated antibodies in tumors. Cancer Res 2006;66:1434-1445
16. Yafai Y, Yang XM, Niemeyer M, Nishiwaki A, Lange J, Wiedemann P et al. Anti-Angiogenic effects of the receptor tyrosine kinase inhibitor, pazopanib, on choroidal neovascularization in rats. Eur J Pharmacol 2011;666:12-18
17. Tobe T, Okamoto N, Vinores MA, Derevjanik NL, Vinores SA, Zack DJ et al. Evolution of neovascularization in mice with overexpression of vascular endothelial growth factor in photoreceptors. Invest Ophthalmol Vis Sci 1998;39:180-188
18. Campos M, Amaral J, Becerra SP, Fariss RN. A novel imaging technique for experimental choroidal neovascularization. Invest Ophthalmol Vis Sci 2006;47:5163-5170
19. Rixe O, Bukowski RM, Michaelson MD, Wilding G, Hudes GR, Bolte O et al. Axitinib treatment in patients with cytokine-refractory metastatic renal-cell cancer: A phase II study. Lancet Oncol 2007;8:975-984
20. Cohen EE, Rosen LS, Vokes EE, Kies MS, Forastiere AA, Worden FP et al. Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: Results from a phase II study. J Clin Oncol 2008;26:4708-4713
21. Schiller JH, Larson T, Ou SH, Limentani S, Sandler A, Vokes E et al. Efficacy and safety of axitinib in patients with advanced non-small-cell lung cancer: Results from a phase II study. J Clin Oncol 2009;27:3836-3841
22. Kernt M, Staehler M, Stief C, Kampik A, Neubauer AS. Resolution of macular oedema in occult choroidal neovascularization under oral Sorafenib treatment. Acta Ophthalmol 2008;86:456-458
23. Diago T, Pulido JS, Molina JR, Collet LC, Link TP, Ryan EH Jr. Ranibizumab combined with low-dose sorafenib for exudative age-related macular degeneration. Mayo Clin Proc 2008;83:231-234
24. Safety and efficacy of eral PTK787 in Patients with subfoveal choroidal neovascularization secondary to age-related macular degeneration (AMD) (ADVANCE). Available at: Http://www.clinicaltrials.gov/ct2/show/ NCT00138632?order=1
25. A study to evaluate the pharmacodynamics, safety, and pharmacokinetics of pazopanib drops in adult subjects with neovascular AMD. Available at: Http://www.clinicaltrials. gov/ct2/show/NCT00612456?order=1
26. CATT Research Group, Martin DF, Maguire MG, Ying GS, Grunwald JE, Fine SL, Jaffe GJ. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med 2011;364:1897-1908
27. Lux A, Llacer H, Heussen FM, Joussen AM. Non-responders to bevacizumab (Avastin) therapy of choroidal neovascular lesions. Br J Ophthalmol 2007;91:1318-1322
28. Hoeben A, Landuyt B, Highley MS, Wildiers H, Van Oosterom AT et al. Vascular endothelial growth factor and angiogenesis. Pharmacol Rev 2004;56:549-580
29. Jo N, Mailhos C, Ju M, Cheung E, Bradley J, Nishijima K et al. Inhibition of platelet-derived growth factor B signaling enhances the efficacy of anti-vascular endothelial growth factor therapy in multiple models of ocular neovascularization. Am J Pathol 2006;168:2036-2053
30. Bergers G, Song S, Meyer-Morse N, Bergsland E, Hanahan D. Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. J Clin Invest 2003;111:1287-1295
31. Erber R, Thurnher A, Katsen AD, Groth G, Kerger H, Hammes HP et al. Combined inhibition of VEGF and PDGF signaling enforces tumor vessel regression by interfering with pericyte-mediated endothelial cell survival mechanisms. FASEB J 2004;18:338-340